Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Return on Sales (2016 - 2025)

Oramed Pharmaceuticals filings provide 8 years of Return on Sales readings, the most recent being 0.36% for Q4 2025.

  • Quarterly Return on Sales changed N/A to 0.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.36% through Dec 2025, changed N/A year-over-year, with the annual reading at 0.36% for FY2025, N/A changed from the prior year.
  • Return on Sales hit 0.36% in Q4 2025 for Oramed Pharmaceuticals, up from 0.22% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.36% in Q4 2025 and bottomed at 0.17% in Q2 2022.
  • Average Return on Sales over 4 years is 0.03%, with a median of 0.09% recorded in 2021.
  • Peak annual rise in Return on Sales hit 16bps in 2023, while the deepest fall reached 1bps in 2023.
  • Oramed Pharmaceuticals' Return on Sales stood at 0.09% in 2021, then crashed by -59bps to 0.14% in 2022, then skyrocketed by 119bps to 0.03% in 2023, then surged by 1277bps to 0.36% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Return on Sales are 0.36% (Q4 2025), 0.22% (Q3 2025), and 0.12% (Q2 2025).